Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337194 · ClinicalTrials.gov registry record · Phase 2
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
A Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00337194: Completed Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI).
NCT00337194 is a Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants, roughly in line with the 28-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00337194, a Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase II trial studies the side effects and how well giving monoclonal antibody SGN-30 together with combination chemotherapy works in treating patients with Hodgkin lymphoma that has returned after a period of improvement or did not respond to previous treatment. Monoclonal antibodies, such as SGN-30, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride, vinorelbine tartrate, and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody SGN-30 together with combination chemotherapy may kill more cancer cells and shrink tumors.
Primary Outcome
The number of participants who respond (complete or partial) to treatment. Response was defined using the revised criteria for malignant lymphoma. Complete response (CR): complete disappearance of all detectable disease; partial response (PR): \>= 50% reduction in sum of the product of diameters of indicator lesions.
Conditions Studied
Interventions
- OTHER placebo
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG gemcitabine hydrochloride
- DRUG vinorelbine tartrate
- BIOLOGICAL monoclonal antibody SGN-30
Study Locations (1)
Illinois
- Cancer and Leukemia Group B - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
What the finished NCT00337194 record still lists
NCT00337194 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, roughly in line with the 28-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target.
The record links to 5 conditions, with Recurrent Adult Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT00337194 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00337194 about?
NCT00337194 is a clinical study titled "SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma". This randomized phase II trial studies the side effects and how well giving monoclonal antibody SGN-30 together with combination chemotherapy works in treating patients with Hodgkin lymphoma that has returned after a period of improvement or did not respond to previous treatment. Monoclonal antibodi...
What is the current status of trial NCT00337194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-04. Estimated completion is 2014-10.
What conditions does trial NCT00337194 study?
This clinical trial studies the following conditions: Recurrent Adult Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma.
What interventions are being tested in trial NCT00337194?
The interventions under investigation include: placebo (OTHER), pegylated liposomal doxorubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG), vinorelbine tartrate (DRUG), monoclonal antibody SGN-30 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00337194?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00337194 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
COMPLETED · Phase 1
-
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia